Pfizer: combination approved for NSCLC
(CercleFinance.com) - Pfizer announces that the US FDA has approved its Braftovi + Mektovi combination for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring a BRAF V600E mutation.
This approval is based on data from the Pharos Phase II clinical trial (NCT03915951), which met its primary efficacy endpoints of objective response rate (ORR) and duration of response (DOR).
The US pharmaceutical company holds exclusive rights to Braftovi and Mektovi in the US and Canada, as well as in all countries of Latin America, Africa and the Middle East.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
This approval is based on data from the Pharos Phase II clinical trial (NCT03915951), which met its primary efficacy endpoints of objective response rate (ORR) and duration of response (DOR).
The US pharmaceutical company holds exclusive rights to Braftovi and Mektovi in the US and Canada, as well as in all countries of Latin America, Africa and the Middle East.
Copyright (c) 2023 CercleFinance.com. All rights reserved.